{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:49:15Z","timestamp":1785829755065,"version":"3.56.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Osteosarcoma remains difficult to cure once it metastasizes, recurs, or becomes resistant to chemotherapy. Surgery combined with multi-drug chemotherapy improves outcomes in localized disease, but outcomes for high-risk patients have plateaued, prompting renewed interest in immunotherapy. However, immune checkpoint blockade has limited efficacy in unselected osteosarcoma patients: in SARC028, one objective response was observed among 22 patients with osteosarcoma treated with pembrolizumab. This limited response is consistent with antigen heterogeneity, enrichment of immunosuppressive myeloid populations, insufficient cytotoxic lymphocyte infiltration, matrix-associated immune exclusion, and metastatic immune adaptation. Gene-based immunotherapy offers a complementary strategy. When endogenous immune priming is inadequate, these platforms may initiate, reshape, or amplify antitumor immunity by promoting oncolytic antigen release, local cytokine or chemokine expression, engineered immune-cell recognition, or non-viral delivery of immunomodulatory payloads. This article discusses oncolytic vectors, cytokine-armed vectors, CAR-T and CAR-NK cells, TCR- or neoantigen-directed strategies, and non-viral gene delivery systems as potential approaches for reshaping osteosarcoma immunity. It also examines combination strategies and translational challenges in pediatric and adolescent patients. Beyond summarizing platform-level evidence, we distinguish findings generated directly in osteosarcoma from evidence extrapolated from other tumor types, identify the principal unresolved knowledge gaps for each platform, and summarize the current osteosarcoma-specific clinical trial landscape to clarify the translational maturity of these strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1920347","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:31:44Z","timestamp":1785828704000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Gene-based immunotherapy in osteosarcoma: from oncolytic vectors to engineered immune cells"],"prefix":"10.3389","volume":"17","author":[{"given":"Junliang","family":"Jia","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuliang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing therapy for osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11912-021-01053-7","article-title":"Update on osteosarcoma","volume":"23","author":"Belayneh","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq276","article-title":"Osteosarcoma","volume":"21","author":"Ritter","year":"2010","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","article-title":"Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.1038\/s41467-022-34689-5","article-title":"Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14398","article-title":"Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma","volume":"111","author":"Deng","year":"2020","journal-title":"Cancer Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100604","article-title":"Single-cell transcriptional profiling in osteosarcoma and the effect of neoadjuvant chemotherapy on the tumor microenvironment","volume":"46","author":"He","year":"2024","journal-title":"J Bone Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2105","article-title":"Losartan blocks osteosarcoma-elicited monocyte recruitment, and combined with the kinase inhibitor toceranib, exerts significant clinical benefit in canine metastatic osteosarcoma","volume":"28","author":"Regan","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/v16071139","article-title":"Oncolytic viral therapy in osteosarcoma","volume":"16","author":"Karadimas","year":"2024","journal-title":"Viruses"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2016.12.001","article-title":"Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: a new hope","volume":"9","author":"Garcia-Moure","year":"2017","journal-title":"J Bone Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1899","article-title":"The oncolytic adenovirus VCN-01 as therapeutic approach against pediatric osteosarcoma","volume":"22","author":"Mart\u00ednez-V\u00e9lez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0565","article-title":"Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune memory","volume":"21","author":"Martinez-Velez","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.100736","article-title":"Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma","volume":"31","author":"Makielski","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cells13040351","article-title":"The development and characterization of a next-generation oncolytic virus armed with an anti-PD-1 sdAb for osteosarcoma treatment in vitro","volume":"13","author":"Higgins","year":"2024","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2900","article-title":"Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients","volume":"23","author":"Streby","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25464","article-title":"A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report","volume":"62","author":"Kolb","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000710","article-title":"Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety","volume":"8","author":"Ge","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/acg2.99","article-title":"Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells","volume":"4","author":"Cao","year":"2021","journal-title":"Adv Cell Gene Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008025","article-title":"Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Mol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2778","article-title":"Genetically modified T cells targeting interleukin-11 receptor \u03b1-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases","volume":"72","author":"Huang","year":"2012","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0075","article-title":"Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells","volume":"23","author":"Fern\u00e1ndez","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B28","article-title":"GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas","volume":"10","author":"Chulanetra","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1186\/s12885-022-10229-8","article-title":"B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009221","article-title":"Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma","volume":"12","author":"Lake","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3298","article-title":"Redirecting B7-H3.CAR T cells to chemokines expressed in osteosarcoma enhances homing and antitumor activity in preclinical models","volume":"30","author":"Talbot","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","article-title":"Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy","volume":"42","author":"Kaczanowska","year":"2024","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg9814","article-title":"Payload-delivering engineered \u03b3\u03b4 T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma","volume":"16","author":"Fowler","year":"2024","journal-title":"Sci Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70140","article-title":"Enhancement of anti\u2010sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2\u2010targeted CAR","volume":"15","author":"Lam","year":"2025","journal-title":"Clin Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112796","article-title":"Approaches to enhance natural killer cell-based immunotherapy for pediatric solid tumors","volume":"13","author":"Quamine","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512520","article-title":"Promise and challenges of T cell immunotherapy for osteosarcoma","volume":"24","author":"Park","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071125","article-title":"Gene and cell therapy for sarcomas: a review","volume":"17","author":"Chawla","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1696830","article-title":"Current landscape of CAR-therapy for osteosarcoma and rhabdomyosarcoma","volume":"16","author":"Stavrou","year":"2025","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115838","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors: a review of the intricate mechanisms and potential strategies","volume":"168","author":"Arora","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.dist.2026.100012","article-title":"Next-generation CAR-T combinations: integrating nanomedicine, metabolic reprogramming, and AI for solid tumor targeting","volume":"2","author":"Sharma","year":"2026","journal-title":"Dis Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.126","article-title":"Phase I\/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma","volume":"17","author":"Chawla","year":"2009","journal-title":"Mol Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202201306","article-title":"Biodegradable carbon dioxide\u2010derived non\u2010viral gene vectors for osteosarcoma gene therapy","volume":"12","author":"Li","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"B44","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12951-023-01961-9","article-title":"Biodegradable FePS3 nanoplatform for efficient treatment of osteosarcoma by combination of gene and NIR-II photothermal therapy","volume":"21","author":"Luo","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S471900","article-title":"Delivery of miRNAs using nanoparticles for the treatment of osteosarcoma","volume":"19","author":"Wang","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113930","article-title":"Advances in mRNA non-viral delivery approaches","volume":"177","author":"Ibba","year":"2021","journal-title":"Adv Drug Delivery Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.589959","article-title":"Advances in lipid nanoparticles for mRNA-based cancer immunotherapy","volume":"8","author":"Guevara","year":"2020","journal-title":"Front Chem"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103895","article-title":"Exosomes in sarcoma: prospects for clinical applications","volume":"181","author":"Ye","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202100133","article-title":"Nanoparticle\u2010mediated STING agonist delivery for enhanced cancer immunotherapy","volume":"21","author":"Zhou","year":"2021","journal-title":"Macromol Biosci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1790067","article-title":"The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights","volume":"17","author":"Ge","year":"2026","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0017","article-title":"Bone cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Biermann","year":"2025","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1920347\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:31:45Z","timestamp":1785828705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1920347\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2026.1920347"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1920347","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1920347"}}